

## **CERTIFICATE OF ANALYSIS**

Page 1 of 2

**Product Description:** V-PLEX® SARS-CoV-2 Panel 34 Kit

Kit Catalog Numbers: K15690U-Series; K15691U-Series; K15693U-Series; K15694U-Series;

K15695U-Series; K15696U-Series

**Kit Lot Number**: K0082435 **Expiration Date**: 28 FEB 2026

# **Kit Components:**

Description	Lot Number	<b>Storage Temperature</b>	Expiration Date
SARS-CoV-2 Plate 34	Z0057440	2-8°C	31 AUG 2026
SULFO-TAG™ Anti-Human IgG Antibody	D00V0030	2-8°C	31 DEC 2026
Reference Standard 1	A0080286	≤ -70°C	28 FEB 2026
Serology Control 1.1	A00C0825	≤ -70°C	31 MAR 2027
Serology Control 1.2	A00C0826	≤ -70°C	31 MAR 2027
Serology Control 1.3	A00C0827	≤-70°C	31 MAR 2027
ACE2 Calibration Reagent	Not Kit Specific	≤ -70°C	See Label
SULFO-TAG™ Human ACE2 Protein	Not Kit Specific	2-8°C	See Label
SULFO-TAG™ Anti-Human IgM Antibody	Not Kit Specific	2-8°C	See Label
SULFO-TAG <sup>TM</sup> Anti-Mouse IgG Antibody	Not Kit Specific	2-8°C	See Label
SULFO-TAG <sup>TM</sup> Anti-Mouse IgM Antibody	Not Kit Specific	2-8°C	See Label
SULFO-TAG <sup>TM</sup> Anti-Mouse IgA Antibody	Not Kit Specific	2-8°C	See Label
Diluent 100	Not Kit Specific	2-8°C	See Label
MSD Blocker A Kit	Not Kit Specific	Room Temperature	See Label
MSD GOLD Read Buffer B	Not Kit Specific	Room Temperature	See Label

See product insert regarding which components are provided with each IgG, IgA, IgM, or ACE2 kit.

# **Plate Uniformity Testing Results:**

Parameter	Precision			Uniformity	Signal
Metric	CV of Intra-plate Averages	Average Intra-plate CV	Max Intra- plate CV	Average Uniformity Metric	Average Signal
SARS-CoV-2 Spike	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 – 1,000,000
SARS-CoV-2 Spike (B.1.1.529; BA.1)	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 – 1,000,000
SARS-CoV-2 Spike (XBB.1)	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 – 1,000,000
SARS-CoV-2 Spike (BF.7)	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 – 1,000,000
SARS-CoV-2 Spike (XBB.1.5)	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 – 1,000,000
SARS-CoV-2 Spike (BQ.1.1)	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 – 1,000,000
SARS-CoV-2 Spike (BA.2.75)	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 - 1,000,000
SARS-CoV-2 Spike (BN.1)	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 – 1,000,000
SARS-CoV-2 Spike (BQ.1)	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 – 1,000,000
SARS-CoV-2 Spike (BA.5)	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 – 1,000,000

COA-20129-A QA-FM-303-C



## **CERTIFICATE OF ANALYSIS**

Page 2 of 2 Coating Confirmation Testing Results:

Spot	Description	Result
1	SARS-CoV-2 Spike	Pass
2	SARS-CoV-2 Spike (B.1.1.529; BA.1)	Pass
3	SARS-CoV-2 Spike (XBB.1)	Pass
4	SARS-CoV-2 Spike (BF.7)	Pass
5	SARS-CoV-2 Spike (XBB.1.5)	Pass
6	SARS-CoV-2 Spike (BQ.1.1)	Pass
7	SARS-CoV-2 Spike (BA.2.75)	Pass
8	SARS-CoV-2 Spike (BN.1)	Pass
9	SARS-CoV-2 Spike (BQ.1)	Pass
10	SARS-CoV-2 Spike (BA.5)	Pass

# **Functional Testing Results:**

Sample Type	Calibrator	Controls		Samples	
Metric	Avg Signal Ratio Test:Reference	Control Recovery	Control Conc. CV	Avg % Difference Test:Reference	Slope Test:Reference
SARS-CoV-2 Spike	50 – 200%	70 – 130%	< 20%	± 25%	0.80 - 1.2
SARS-CoV-2 Spike (B.1.1.529; BA.1)	50 – 200%	70 – 130%	< 20%	± 25%	0.80 - 1.2
SARS-CoV-2 Spike (XBB.1)	50 – 200%	70 – 130%	< 20%	± 25%	0.80 - 1.2
SARS-CoV-2 Spike (BF.7)	50 – 200%	70 – 130%	< 20%	± 25%	0.80 - 1.2
SARS-CoV-2 Spike (XBB.1.5)	50 – 200%	70 – 130%	< 20%	± 25%	0.80 - 1.2
SARS-CoV-2 Spike (BQ.1.1)	50 – 200%	70 – 130%	< 20%	± 25%	0.80 - 1.2
SARS-CoV-2 Spike (BA.2.75)	50 – 200%	70 – 130%	< 20%	± 25%	0.80 - 1.2
SARS-CoV-2 Spike (BN.1)	50 – 200%	70 – 130%	< 20%	± 25%	0.80 - 1.2
SARS-CoV-2 Spike (BQ.1)	50 – 200%	70 – 130%	< 20%	± 25%	0.80 - 1.2
SARS-CoV-2 Spike (BA.5)	50 – 200%	70 - 130%	< 20%	± 25%	0.80 - 1.2

## **Additional Comments:**

Functional testing was executed using SARS-CoV-2 Plate 34 (Z0057440), SULFO-TAG Anti-Human IgG Antibody (D00V0030), Reference Standard 1 (A0080286), and Serology Controls (A00C0825, A00C0826, A00C0827).

All kit components were manufactured and tested according to MSD documents. The lots listed in the Kit Components table meet MSD's specifications.

### **Statement:**

The above product is intended for Research Use Only. Not for use in Diagnostic Procedures.

	Name	Function	Signature	Date
Review/Approval	Karen Hamilla	Quality	Laur Hamille	01 APR 2024

COA-20129-A QA-FM-303-C